Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1799]
News [2694]
Articles [198]
Editorials [1]
Conferences [135]
elearning [13]
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for...
Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, Lille...
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for multiple myeloma ( Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, Lille, France )
18 Dec 2013
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia...
Dr Richard Furman - New York Weill Cornell Medical Center, USA
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL) ( Dr Richard Furman - New York Weill Cornell Medical Center, USA )
17 Dec 2013
Comment: Transplantation and short telomeres increase the risk of cognitive...
Dr Jeffrey Miller - University of Minnesota, Minneapolis, USA
Comment: Transplantation and short telomeres increase the risk of cognitive impairment ( Dr Jeffrey Miller - University of Minnesota, Minneapolis, USA )
17 Dec 2013
New agents in CLL
Dr Jacqueline Barrientos - LIJ Medical Center, New York, USA
New agents in CLL ( Dr Jacqueline Barrientos - LIJ Medical Center, New York, USA )
13 Dec 2013
Chronic lymphocytic leukaemia: A new treatment era is born
Dr John Gribben - Barts Cancer Institute, London, UK
Chronic lymphocytic leukaemia: A new treatment era is born ( Dr John Gribben - Barts Cancer Institute, London, UK )
13 Dec 2013
NeoALTTO trial indicates breast cancer patients who had pathologic complete...
Prof Martine Piccart-Gebhart - Jules Bordet Institute, Brussels, Belgium
NeoALTTO trial indicates breast cancer patients who had pathologic complete response had improved event-free and overall survival ( Prof Martine Piccart-Gebhart - Jules Bordet Institute, Brussels, Belgium )
12 Dec 2013
Immune cells in tumours may identify breast cancer patients most likely to...
Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Immune cells in tumours may identify breast cancer patients most likely to benefit from trastuzumab ( Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
12 Dec 2013
BETH study: highly effective treatment option for patients with HER2 breast...
Dr Dennis Slamon - University of California, Los Angeles
BETH study: highly effective treatment option for patients with HER2 breast cancer ( Dr Dennis Slamon - University of California, Los Angeles )
12 Dec 2013
Screening mammography, over diagnosis and over treatment
Dr Gilbert Welch - Dartmouth College, Hanover, USA
Screening mammography, over diagnosis and over treatment ( Dr Gilbert Welch - Dartmouth College, Hanover, USA )
12 Dec 2013
Initial phase III results of the first trial in newly diagnosed multiple myeloma
Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, France
Initial phase III results of the first trial in newly diagnosed multiple myeloma ( Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, France )
10 Dec 2013
Effective treatment of chemotherapy-refractory diffuse large B cell lymphoma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Effective treatment of chemotherapy-refractory diffuse large B cell lymphoma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
7 Dec 2013
Toxicity complications from chemotherapy in lung cancer treatment
Dr G.S. Bhattacharyya - FORTIS Hospitals, Kolkata, India
Toxicity complications from chemotherapy in lung cancer treatment ( Dr G.S. Bhattacharyya - FORTIS Hospitals, Kolkata, India )
5 Dec 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation